Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

Autor Escudier, B, Michaelson, M D, Motzer, R J, Hutson, T E, Clark, J I, Lim, H Y, Porfiri, E, Zalewski, P, Kannourakis, G, Staehler, M, Tarazi, J, Rosbrook, B, Cisar, L, Hariharan, S, Kim, S, Rini, B I
Vydáno 2014

Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population(†)

Autor Renfro, L. A., Grothey, A., Kerr, D., Haller, D. G., André, T., Van Cutsem, E., Saltz, L., Labianca, R., Loprinzi, C. L., Alberts, S. R., Schmoll, H., Twelves, C., Yothers, G., Sargent, D. J., Sargent, D.J., Green, E., Grothey, A., Alberts, S.R., Shi, Q., Renfro, L.A., Yothers, G., O'Connell, M.J., Wolmark, N., de Gramont, A., Gray, R., Kerr, D., Haller, D.G., Guthrie, K., Buyse, M., Labianca, R., Seitz, J.F., O'Callaghan, C.J., Francini, G., Catalano, P.J., Blanke, C.D., Andre, T., Goldberg, R.M., Benson, A., Twelves, C., Sirzen, F., Cisar, L., Van Cutsem, E., Saltz, L.
Vydáno v Ann Oncol (2015)